Table 3.

Logistic regression model predicting the likelihood of hemoglobin levels exceeding 13 g/dl: Results from model 2

PredictorHemoglobin 13 g/dl
Chi-squarePOdds Ratio (95% CI)
Hemoglobin in month 4
    <11244.74<0.00010.70 (0.67 to 0.73)
    11 to <11.569.98<0.00010.81 (0.77 to 0.85)
    11.5 to <121
    12 to <131221.13<0.00011.99 (1.91 to 2.07)
    ≥137201.74<0.00016.31 (6.05 to 6.59)
ESA dose in month 4
    <25200588.94<0.00010.60 (0.57 to 0.62)
    25,200 to <44,800187.81<0.00010.76 (0.73 to 0.79)
    44,800 to <71,5001
    71,500 to <119,600237.10<0.00011.33 (1.29 to 1.38)
    ≥119,600559.95<0.00011.56 (1.51 to 1.62)
Iron in months 1 through 4
    none1
    intermittent130.19<0.00011.69 (1.54 to 1.85)
    maintenance114.76<0.00011.67 (1.52 to 1.83)
ESA dosage change, month 3 to 4
    decrease2.700.100.93 (0.85 to 1.01)
    stable1
    increase291.73<0.00012.14 (1.96 to 2.33)
Interaction of iron in month 4 and ESA dose change
    intermittent iron, decreasing dose16.46<0.00010.81 (0.73 to 0.90)
    intermittent iron, increasing dose24.21<0.00010.77 (0.70 to 0.86)
    maintenance iron, decreasing dose11.900.000.83 (0.75 to 0.92)
    maintenance iron, increasing dose23.40<0.00010.77 (0.69 to 0.85)
Age, yrs
    <204.240.041.30 (1.01 to 1.67)
    20 to 440.000.961.00 (0.96 to 1.04)
    45 to 641
    65 to 740.250.621.01 (0.98 to 1.04)
    ≥752.560.10971.03 (0.99 to 1.06)
Sex
    female0.760.380.99 (0.96 to 1.01)
    male1
Race
    White1
    African American6.720.011.04 (1.01 to 1.06)
    other9.840.001.09 (1.03 to 1.14)
Primary cause of ESRD
    diabetes1
    glomerulonephritis0.490.480.98 (0.94 to 1.03)
    hypertension1.130.291.02 (0.98 to 1.06)
    other0.440.511.01 (0.97 to 1.06)
Comorbidity conditions
    atherosclerotic heart disease23.83<0.00011.09 (1.05 to 1.12)
    cancer14.360.000.88 (0.83 to 0.94)
    cardiac other3.170.071.03 (1.00 to 1.07)
    congestive heart failure0.040.851.00 (0.97 to 1.04)
    COPD7.000.011.06 (1.02 to 1.11)
    CVA/TIA16.74<0.00011.10 (1.05 to 1.16)
    diabetes0.610.430.99 (0.95 to 1.02)
    dysrhythmia6.760.010.95 (0.92 to 0.99)
    gastrointestinal bleeding1.570.211.04 (0.98 to 1.10)
    liver disease0.070.790.99 (0.95 to 1.04)
    peripheral vascular disease9.480.001.05 (1.02 to 1.09)
Provider
    DaVita853.53<0.00011.71 (1.65 to 1.77)
    DCI665.99<0.00010.32 (0.29 to 0.35)
    Fresenius129.79<0.00011.21 (1.17 to 1.25)
    Gambro155.63<0.00011.27 (1.22 to 1.32)
    hospital2.150.141.05 (0.98 to 1.12)
    independent15.55<0.00011.08 (1.04 to 1.11)
    national8.420.000.80 (0.69 to 0.93)
    RCG61.03<0.00011.19 (1.14 to 1.24)
Intermittent vs. no iron, months 1 through 4
    dose decrease, month 3 to 4147.56<0.00011.37 (1.30 to 1.44)
    dose stable, month 3 to 4130.19<0.00011.69 (1.54 to 1.85)
    dose increase, month 3 to 454.93<0.00011.40 (1.28 to 1.53)
Intermittent vs. maintenance iron, months 1 through 4
    dose decrease, month 3 to 41.370.241.06 (0.96 to 1.18)
    dose stable, month 3 to 40.150.701.01 (0.94 to 1.09)
    dose increase, month 3 to 43.120.081.10 (0.99 to 1.22)
  • Reference groups: ages 45 to 64 yr, male, white, diabetes as primary cause of end-stage renal disease, no comorbid conditions, average of all providers, baseline hemoglobin level 11.5 to <12, baseline ESA dosage 44,800 to <71,500, no iron in months 1 through 4, stable ESA dose from month 3 to month 4. COPD, chronic obstructive pulmonary disease; CVA/TIA, cerebrovascular accident/transient ischemic attack; ESAs, erythropoiesis stimulating agents.